Immunicom

Executive Summary

Immunicom is a clinical-stage biotechnology company pioneering a novel, non-pharmacologic immunotherapy platform called Immunopheresis™. Its lead device, LW-02, operates by extracorporeally removing specific immunosuppressive proteins—such as soluble checkpoint molecules—from a patient's blood. This process aims to reactivate the body's natural immune response against cancer and other diseases, offering a potential therapeutic alternative that avoids the systemic side effects typical of drug-based immunotherapies. By targeting the immunosuppressive tumor microenvironment directly, LW-02 could improve patient quality of life while maintaining or enhancing antitumor activity. The platform represents a paradigm shift in immunotherapy, leveraging a device-based approach to modulate the immune system. Currently, Immunicom is advancing LW-02 through clinical development, with initial studies focusing on safety and feasibility in solid tumors. The company's strategy includes pursuing regulatory designations to accelerate development and exploring partnerships to broaden the platform's application. If successful, Immunopheresis could address a large unmet need in oncology, particularly for patients who are refractory to existing treatments or experience severe side effects. As the platform is modality-agnostic, it may also be applicable to autoimmune diseases, expanding its market potential. Immunicom's innovative approach and early clinical data position it as a compelling player in the immunotherapy landscape.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase II trial for LW-02 in metastatic cancer60% success
• Q2 2026FDA Fast Track designation for LW-0275% success
• Q3 2026Strategic partnership with a global pharmaceutical company50% success